Zevra Therapeutics (NASDAQ:ZVRA) Raised to "Strong-Buy" at Wall Street Zen

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report released on Saturday.

Several other analysts have also issued reports on ZVRA. Cantor Fitzgerald increased their price objective on Zevra Therapeutics from $25.00 to $29.00 and gave the stock an "overweight" rating in a report on Thursday, July 10th. Citigroup restated an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. Finally, HC Wainwright started coverage on Zevra Therapeutics in a research note on Wednesday, July 2nd. They set a "buy" rating and a $26.00 price objective on the stock. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $23.71.

Zevra Therapeutics Price Performance

Shares of ZVRA traded down $0.04 during mid-day trading on Friday, hitting $12.75. The company's stock had a trading volume of 1,243,533 shares, compared to its average volume of 724,501. Zevra Therapeutics has a 1-year low of $5.45 and a 1-year high of $13.15. The firm has a market capitalization of $697.12 million, a P/E ratio of -6.70 and a beta of 1.97. The firm has a 50-day simple moving average of $9.06 and a 200 day simple moving average of $8.20. The company has a current ratio of 3.02, a quick ratio of 2.93 and a debt-to-equity ratio of 1.46.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.15. Zevra Therapeutics had a negative return on equity of 201.05% and a negative net margin of 226.78%. The firm had revenue of $20.40 million during the quarter, compared to the consensus estimate of $16.96 million. During the same quarter in the previous year, the business earned ($0.40) earnings per share. Analysts predict that Zevra Therapeutics will post -1.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Zevra Therapeutics

A number of institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets purchased a new position in shares of Zevra Therapeutics during the fourth quarter worth $53,000. GAMMA Investing LLC boosted its stake in Zevra Therapeutics by 20,564.1% during the 1st quarter. GAMMA Investing LLC now owns 8,059 shares of the company's stock worth $60,000 after purchasing an additional 8,020 shares during the period. Strs Ohio acquired a new stake in shares of Zevra Therapeutics in the 1st quarter worth $125,000. Squarepoint Ops LLC lifted its stake in shares of Zevra Therapeutics by 36.1% in the fourth quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock valued at $138,000 after purchasing an additional 4,384 shares during the period. Finally, ProShare Advisors LLC purchased a new stake in shares of Zevra Therapeutics during the fourth quarter worth about $145,000. 35.03% of the stock is owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.